Quarterly report pursuant to Section 13 or 15(d)

Unaudited Condensed Consolidated Balance Sheets

v3.23.1
Unaudited Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2023
Jun. 30, 2022
Current assets:    
Cash and cash equivalents $ 33,743 $ 150,410
Investments in marketable debt securities 69,319  
Prepaid expenses and other 2,464 1,694
Total current assets 105,526 152,104
Long-term assets:    
Investments in marketable debt securities 26,210  
Right-of-use assets 2,172 152
Property and equipment, net 149 16
Deposits and other 148 148
Total assets (134,205) (152,420)
Current liabilities:    
Accounts payable 2,947 1,132
Accrued liabilities:    
Accrued clinical and other 1,121 979
Insurance premiums   243
Current portion of operating lease liabilities 319 108
Total current liabilities 4,387 2,462
Long term liabilities:    
Operating lease liabilities, net of current portion 2,055 80
Embedded derivative liabilities 447 407
Total liabilities 6,889 2,949
Commitments and contingencies (Notes 5, 9 and 10)
Shareholders' equity:    
Preferred stock, $0.001 par value; 400 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 100,000 shares authorized; issued and outstanding 36,827 and 33,582 shares as of March 31, 2023 and June 30, 2022, respectively 37 34
Additional paid-in capital 375,668 358,635
Accumulated other comprehensive loss (132)  
Accumulated deficit (248,257) (209,198)
Total shareholders' equity 127,316 149,471
Total liabilities and shareholders' equity $ 134,205 $ 152,420